Abstract |
The COVID-19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT-P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment benefitting patients both during the pandemic and beyond.
|
Authors | Sooraj Vijayan, Kyungmin Hwangbo, Nick Barkham |
Journal | Clinical case reports
(Clin Case Rep)
Vol. 10
Issue 1
Pg. e05233
(Jan 2022)
ISSN: 2050-0904 [Print] England |
PMID | 35059197
(Publication Type: Case Reports)
|
Copyright | © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. |